Size: px
Start display at page:

Download ""

Transcription

1 Overall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario Sznol, 3 Christopher D. Lao, 4 Rene Gonzalez, 5 Gregory A. Daniels, 6 Michael Smylie, 7 Ragini R. Kudchadkar, 8 John A. Thompson, 9 William H. Sharfman, Michael B. Atkins, Anna C. Pavlick, 2 Joel Jiang, 3 Alexandre Avila, 3 Sheena Demelo, 3 F. Stephen Hodi 4 Princess Margaret Cancer Centre, Toronto, ON, Canada; 2 Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3 Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA; 4 University of Michigan, Ann Arbor, Michigan, USA; 5 University of Colorado Cancer Center, Aurora, CO, USA; 6 University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA; 7 Cross Cancer Institute, Edmonton, Alberta, Canada; 8 Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, USA; 9 University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC, USA; 2 New York University Langone Medical Center, New York, NY, USA; 3 Bristol-Myers Squibb, Princeton, NJ, USA; 4 Dana-Farber Cancer Institute, Boston, MA, USA david.hogg@uhn.ca

2 Background Nivolumab (NIVO; anti-pd-) and ipilimumab (IPI; anti-ctla-4), alone and in combination, are approved for the treatment of advanced melanoma (MEL),2 Phase II and III trials showed improved efficacy for NIVO+IPI vs IPI alone in patients with MEL, but with a higher frequency of adverse events (AEs) 3,4 In the phase II CheckMate 69 trial, the 2-year overall survival (OS) rate was 64% for all patients in the NIVO+IPI group vs 45% for IPI (-year rates were 73% and 65%) 5 In the phase III CheckMate 67 trial, 2-year OS rates were 64% for NIVO+IPI, 59% for NIVO, and 45% for IPI (-year rates were 73%, 74%, and 67%, respectively) 6. OPDIVO (nivolumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb; YERVOY (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb; October Larkin J et al. N Engl J Med. 25;373: Postow MA et al. N Engl J Med. 25;372: Postow MA et al. Presented at the AACR 26 meeting. Abstract CT2. 6. Larkin J et al. Presented at the AACR 27 Annual Meeting. Abstract CT75. 2

3 CheckMate 28 CheckMate 28 (NCT286249) is a North American expanded access program (EAP) Objective was to provide NIVO+IPI combination therapy in patients with MEL who may have progressed on other therapies, but who were treatment-naïve for anti-ctla-4 and anti-pd- United States (US) cohort: 58 treated patients with a minimum follow-up of year Canada cohort: 52 treated patients with a minimum follow-up of 6 months We previously reported safety data on 252 patients treated in the US with 6 months of follow-up Here, we report the first OS data for all patients, as well as updated safety data in all patients. Chapman PB et al. Presented at the ASCO 26 Annual Meeting. Abstract

4 Study Design and Assessments NIVO mg/kg + IPI 3 mg/kg Q3W 4 NIVO 3 mg/kg Q2W Treat until progression or unacceptable toxicity (48 weeks maximum) Safety assessments included the incidence of treatment-related Aes and select AEs (ie, those with a potential immunologic etiology) Overall survival was analyzed for all patients based on Kaplan-Meier survival curves Anti-tumor response assessments were not captured within the EAP 4

5 Patient Demographics, Characteristics, and Disposition Total (N=732) Of 732 treated patients, 3% had received prior therapies US (n=58) Canada (n=52) Male, n (%) 466 (64) 366 (63) (66) Median age, (range) 59 (8 87) 59 (8 87) 57 (27 8) BRAF mutant, n (%) 36 (43) 24 (4) 76 (5) LDH > ULN, n (%) 226 (3) 69 (29) 57 (38) LDH > 2x ULN, n (%) 69 (9) 53 (9) 6 () M stage at study entry, n (%) M 76 () 65 () (7) Ma 98 (3) 8 (4) 8 (2) Mb 37 (9) 99 (7) 38 (25) Mc with brain metastases 9 (2) 7 (2) 2 (3) Mc without brain metastases 286 (39) 223 (38) 63 (4) Median duration of therapy was.8 months for NIVO and.4 months for IPI Median number of NIVO+IPI combination doses was 3 (range: -4) and 44% of patients continued onto NIVO maintenance Overall, at the time of database lock, 9% of patients were still receiving treatment LDH = lactate dehydrogenase; ULN = upper limit of normal 5

6 OS (%) Overall Survival CheckMate 28 and Clinical Trials Events/number at risk Median OS, Months (95% CI) Number of patients at risk NIVO+IPI 27/732 NR (NR, NR) % Months NIVO+IPI CI = confidence interval; NR = not reached 6

7 OS (%) Overall Survival for LDH Subpopulations Events/number at risk Median OS, Months (95% CI) Number of patients at risk % 7 Months LDH ULN 47/462 NR (NR, NR) LDH > ULN 7/ (3.4, NR) LDH > 2 ULN 29/69.5 (7.5, NR) 6 6% % LDH ULN LDH > ULN LDH > 2 ULN CI = confidence interval; LDH = lactate dehydrogenase; NR = not reached; ULN = upper limit of normal 7

8 OS (%) Overall Survival for Melanoma Subtype Subpopulation Events/number at risk Median OS, Months (95% CI) Number of patients at risk 9 Mucosal / (3.5, NR) Ocular/Uveal / (6., NR) % % Months Mucosal Ocular/uveal CI = confidence interval; NR = not reached 8

9 Overall Safety Summary Total patients (N=732) n (%) Any grade Grade 3/4 Patients with any treatment-related AE 686 (94) 364 (5) Patients with treatment-related AEs leading to discontinuation 235 (32) 84 (25) Treatment-related deaths a 4 () Treatment-related select (immune-related) AEs were similar to clinical trial studies Most common all grade AEs were skin (62%), gastrointestinal (43%), and hepatic (33%) Most common grade 3-4 AEs were gastrointestinal (6%), hepatic (4%), and skin (5%) a Includes multiorgan failure, congestive heart failure, sepsis due to grade 4 colitis, and diffuse myositis and myocarditis. 9

10 Conclusions This large EAP of North American patients showed -year OS rates consistent with those reported in clinical trials in patients with untreated MEL Although -year survival rates were decreased in poor prognostic subgroups, OS was still >4% in patients with elevated LDH and those with ocular/uveal MEL subtypes -year OS rates were 73% for NIVO+IPI in both CheckMate 69 and 67 2 in treatment-naive patients with advanced MEL Grade 3-4 treatment-related AEs were reported in 5% of patients No new safety signals were identified NIVO+IPI treatment demonstrated survival outcomes and a safety profile consistent with clinical trial data in this real-world population. Postow MA et al. Presented at the AACR 26 meeting. Abstract CT2. 2. Larkin J et al. Presented at the AACR 27 Annual Meeting. Abstract CT75.

Immunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center

Immunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated

More information

Melanoma brain mets management

Melanoma brain mets management Melanoma brain mets management Reinhard Dummer, Phil Cheng, Simone Goldinger, Katrin Kerl, Lars French, Joanna Mangana, Lukas Sommer, Ralph Braun, Mitch Levesque Substantially worse survival in patients

More information

III Sessione I risultati clinici

III Sessione I risultati clinici 10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it

More information

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single

More information

Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin

Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors

More information

New paradigms for treating metastatic melanoma

New paradigms for treating metastatic melanoma New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall

More information

Immunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)

Immunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS) Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers

More information

Índice. Melanoma Cáncer de Pulmón Otros tumores

Índice. Melanoma Cáncer de Pulmón Otros tumores Índice Melanoma Cáncer de Pulmón Otros tumores Carcinoma de Vejiga Carcinoma de Células Renales Carcinoma de Cabeza y Cuello Carcinomas del tubo digestivo Cáncer de Mama MELANOMA CIRUGÍA CIRUGÍA + INFa

More information

PTAC meeting held on 5 & 6 May (minutes for web publishing)

PTAC meeting held on 5 & 6 May (minutes for web publishing) PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and

More information

AACR 2018 Investor Meeting

AACR 2018 Investor Meeting AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for

More information

Bristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA

Bristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA 3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer

More information

CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer

CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,

More information

Treatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC

Treatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off

More information

New Systemic Therapies in Advanced Melanoma

New Systemic Therapies in Advanced Melanoma New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity

More information

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells

More information

Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background

Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal

More information

What we learned from immunotherapy in the past years

What we learned from immunotherapy in the past years What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure

More information

Immunotherapy of Melanoma Sanjiv S. Agarwala, MD

Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma

More information

Immunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto

Immunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf

More information

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March

More information

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy

More information

Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania

Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions

More information

Appendices. Appendix A Search terms

Appendices. Appendix A Search terms Appendices Appendix A Search terms Database Search terms Medline 1. Ipilimumab; 2. MDX-010; 3. MDX-101; 4. Yervoy; 5. BMS-734016; 6. Nivolumab; 7. ONO-4538; 8. BMS-936558; 9. MDX-1106; 10. Opdivo; 11.

More information

ClinicalTrials.gov Identifier: NCT Adi Diab 1, Nizar Tannir 1, Daniel Cho

ClinicalTrials.gov Identifier: NCT Adi Diab 1, Nizar Tannir 1, Daniel Cho Pivot-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma,

More information

Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma

Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,

More information

The Really Important Questions Current Immunotherapy Trials are Not Answering

The Really Important Questions Current Immunotherapy Trials are Not Answering The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway

More information

Characterization of Patients with Poor-

Characterization of Patients with Poor- Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,

More information

ASCO 2014 Highlights*

ASCO 2014 Highlights* ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s

More information

Unmet Need Mucosal and Uveal Melanoma

Unmet Need Mucosal and Uveal Melanoma Unmet Need Mucosal and Uveal Melanoma Matteo Carlino Crown Princess Mary Cancer Centre Westmead and Blacktown Hospitals Melanoma Institute Australia The University of Sydney. Cutaneous Overall Survival

More information

Medical Treatment for Melanoma Sanjiv S. Agarwala, MD

Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview

More information

post Chicago 2016: Thoraxonkologie Helge Bischoff Thoraxonkologie, Thoraxklinik Universität Heidelberg

post Chicago 2016: Thoraxonkologie Helge Bischoff Thoraxonkologie, Thoraxklinik Universität Heidelberg post Chicago 2016: Thoraxonkologie Helge Bischoff Thoraxonkologie, Thoraxklinik Universität Heidelberg Post Chicago 2016: Thoraxonkologie Immuntherapie SCLC Mesotheliom Nachsorge Pembro/ Carbo/Taxol Pembro/

More information

Efficacy and safety of nivolumab plus ipilimumab in previously treated metastatic urothelial carcinoma

Efficacy and safety of nivolumab plus ipilimumab in previously treated metastatic urothelial carcinoma Efficacy and safety of nivolumab plus ipilimumab in previously treated metastatic urothelial carcinoma First results from the phase I/II CheckMate 032 study Padmanee Sharma, 1 Margaret K. Callahan, 2 Emiliano

More information

Combination Approaches in Melanoma: A Balancing Act

Combination Approaches in Melanoma: A Balancing Act Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic

More information

Clinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer

Clinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,

More information

New Therapeutic Approaches to Malignant Melanoma

New Therapeutic Approaches to Malignant Melanoma 2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational

More information

NKTR-214 (CD-122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT

NKTR-214 (CD-122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT NKTR-214 (CD-122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT ClinicalTrials.gov Identifier: NCT02983045 Adi Diab 1, Michael Hurwitz 2,

More information

Immunotherapy Treatment Developments in Medical Oncology

Immunotherapy Treatment Developments in Medical Oncology Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired

More information

Ipilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008

Ipilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008 Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute

More information

Melanoma: Immune checkpoints

Melanoma: Immune checkpoints ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto

More information

Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial

Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,

More information

Cancer Immunotherapy: an Emerging Paradigm

Cancer Immunotherapy: an Emerging Paradigm Cancer Immunotherapy: an Emerging Paradigm Branimir I. Sikic, MD Professor of Medicine Stanford University Nevada Cancer Control Summit Reno, November 6, 217 T-Cell Response: Second Signals to Accelerate

More information

Presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9 12, 2017; Atlanta, GA, USA

Presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9 12, 2017; Atlanta, GA, USA 65 Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 25 Study Jonathon B. Cohen, 1 Andreas

More information

Toxicity from Checkpoint Inhibitors. James Larkin FRCP PhD

Toxicity from Checkpoint Inhibitors. James Larkin FRCP PhD Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech

More information

Yervoy. Yervoy (ipilimumab) Description

Yervoy. Yervoy (ipilimumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 5 Last Review Date: September 15, 2017 Yervoy Description Yervoy (ipilimumab)

More information

Melanoma Update Lynn Schuchter, MD Abramson Cancer Center University of Pennsylvania

Melanoma Update Lynn Schuchter, MD Abramson Cancer Center University of Pennsylvania Melanoma Update 2016 Lynn Schuchter, MD Abramson Cancer Center University of Pennsylvania ASCO 2016 ABSTRACT # STUDY ID AGENT OUTCOME PRESENTER 9503 KEYNOTE 001 PEMBRO 3 YR OS, PFS, ORR 9504 KEYNOTE 006

More information

pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION

pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION The CADTH pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial M inistries of Health (with the exception

More information

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1 Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND

More information

Immunotherapy for Renal Cell Carcinoma. James Larkin

Immunotherapy for Renal Cell Carcinoma. James Larkin Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech

More information

Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes

Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center

More information

for patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to

More information

Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures

Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory

More information

Overview: Immunotherapy in CNS Metastases

Overview: Immunotherapy in CNS Metastases Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris

More information

Immunotherapy Approaches in Lymphoma

Immunotherapy Approaches in Lymphoma Immunotherapy Approaches in Lymphoma John Kuruvilla MD FRCPC 1 Disclosures for John Kuruvilla MD Research Support Employee Leukemia and Lymphoma Society US, Rasch Foundation Roche, N/A Consultant Abbvie,

More information

Elotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)

Elotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM) A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe

More information

ASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine

ASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent

More information

Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy

Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy Philip Mease MD Director, Rheumatology Clinical Research, Swedish- Providence St. Joseph Health Clinical Professor, University of Washington

More information

Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases

Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital

More information

Highlights STOMACH CANCER

Highlights STOMACH CANCER UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria

More information

Nivolumab: esperienze italiane nel carcinoma polmonare avanzato

Nivolumab: esperienze italiane nel carcinoma polmonare avanzato NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale

More information

Renal Cell Carcinoma: Systemic Therapy Progress and Promise

Renal Cell Carcinoma: Systemic Therapy Progress and Promise Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.

More information

6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)

6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC) Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab

More information

Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors

Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors Allison Ackerman, MD, PhD 1 ; Oliver Klein, MD 2 ; David F. McDermott, MD 1 ; Wei Wang, PhD 3

More information

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved

More information

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) ASCO Annual Meeting 2017 Randomized trial of irinotecan and cetuximab with

More information

Review of immunotherapy in melanoma

Review of immunotherapy in melanoma Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology

More information

Special Situation: Brain metastases

Special Situation: Brain metastases ESMO Advanced Course on Unsolved Questions in Immuno-Oncology February 16-17 2018, Amsterdam, Netherlands Special Situation: Brain metastases Matthias Preusser, MD Associate Professor of Medicine Department

More information

Immunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France

Immunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data

More information

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma Buchbinder et al. Journal for ImmunoTherapy of Cancer (2016) 4:52 DOI 10.1186/s40425-016-0155-8 RESEARCH ARTICLE Open Access A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab

More information

HHS Public Access Author manuscript N Engl J Med. Author manuscript; available in PMC 2017 November 22.

HHS Public Access Author manuscript N Engl J Med. Author manuscript; available in PMC 2017 November 22. HHS Public Access Author manuscript Published in final edited form as: N Engl J Med. 2015 July 02; 373(1): 23 34. doi:10.1056/nejmoa1504030. Combined Nivolumab and Ipilimumab or Monotherapy in Previously

More information

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

ONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing

ONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma

More information

New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors

New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors Farah Brasfield, MD Chair, Regional Chiefs of Oncology Kaiser Permanente Jennifer Chang, PharmD, MPH Supervisor, Drug Information Services

More information

MELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone

MELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year

More information

Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma.

Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma. Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma. The National Centre for Pharmacoeconomics (NCPE) has issued a

More information

Debate 1 Are treatments for small cell lung cancer getting better? No:

Debate 1 Are treatments for small cell lung cancer getting better? No: Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University

More information

ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients with advanced cancers

ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients with advanced cancers ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-211 +/- nivolumab (nivo) in patients with advanced cancers Timothy A. Yap 1, Howard A. Burris 2, Shivaani Kummar 3, Gerald

More information

Opdivo. Opdivo (nivolumab) Description

Opdivo. Opdivo (nivolumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:

More information

Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies

Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges

More information

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy

More information

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma Section Editors: Christopher J. Campen and Beth Eaby-Sandy Pembrolizumab: First in Class for Treatment of Metastatic Melanoma CARRIE BARNHART, PharmD From Billings Clinic Cancer Center, Billings, Montana

More information

Yervoy. Yervoy (ipilimumab) Description

Yervoy. Yervoy (ipilimumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 4 Last Review Date: March 18, 2016 Yervoy Description Yervoy (ipilimumab)

More information

Beyond BRAFi/MEKi: Combination and Sequencing Approaches for in Patients with Metastatic BRAF V600 Mutant Melanoma:

Beyond BRAFi/MEKi: Combination and Sequencing Approaches for in Patients with Metastatic BRAF V600 Mutant Melanoma: Beyond BRAFi/MEKi: Combination and Sequencing Approaches for in Patients with Metastatic BRAF V600 Mutant Melanoma: Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi Comprehensive Cancer Center

More information

Melanoma: Therapeutic Progress and the Improvements Continue

Melanoma: Therapeutic Progress and the Improvements Continue Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic

More information

Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016

Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016

More information

Virtual Tumorboards del diagnóstico al tratamiento. Christian Fegeler CENS TechTalks, Santiago de Chile,

Virtual Tumorboards del diagnóstico al tratamiento. Christian Fegeler CENS TechTalks, Santiago de Chile, Virtual Tumorboards del diagnóstico al tratamiento Christian Fegeler CENS TechTalks, Santiago de Chile, 08.03.2018 ... our molecular tumor board (MTB) started in May 2017 weekly conference Multidisciplinary

More information

Immunotherapy, an exciting era!!

Immunotherapy, an exciting era!! Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy

More information

Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico

Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,

More information

Weitere Kombinationspartner der Immunotherapie

Weitere Kombinationspartner der Immunotherapie 1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for

More information

Cancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015

Cancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director

More information

Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series

Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series Lavinia Spain, 1 Gerard Walls, 1 Christina Messiou, 2 Samra Turajlic, 1,3 Martin Gore,

More information

ESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE

ESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future

More information

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates. 6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes

More information

December 8, Attached from the following page is the press release made by BMS for your information.

December 8, Attached from the following page is the press release made by BMS for your information. December 8, 2016 Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced Non-small Cell Lung Cancer, in Updated Phase 1b CheckMate -012

More information

Melanoma. Kevin B. Kim, MD. Clinical Director of Melanoma Clinical Research Program California Pacific Medical Center San Francisco, CA, USA

Melanoma. Kevin B. Kim, MD. Clinical Director of Melanoma Clinical Research Program California Pacific Medical Center San Francisco, CA, USA Melanoma Kevin B. Kim, MD Clinical Director of Melanoma Clinical Research Program California Pacific Medical Center San Francisco, CA, USA Disclosures Received research grant from : (no personal compensation):

More information

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current

More information

Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade

Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING

More information

Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment

Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure

More information

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma The new england journal of medicine Original Article Combined and or Monotherapy in Untreated Melanoma J. Larkin, V. Chiarion Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, D. Schadendorf, R. Dummer,

More information